| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Xiaopeng Li last filed a Form 4 in August 2017, as Director at ORMP. Xiaopeng Li's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 206,350 shares of ORMP. Net of sales, the ORMP filings show accumulation of 142,450 shares.
Xiaopeng Li has 5 Form 4 filings on record from November 2016 to August 2017, all as Director at Oramed Pharmaceuticals (ORMP), 2016–2017.
The 5 reported transactions were 2 open-market purchases, 2 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to 2 purchases worth about $1.1M and no sales.
The largest open-market purchase was 89,636 shares of ORMP at an average $8.50 on August 2, 2017, about $762K.
Shares as reported in the last Form 4 for each company; the most recent is from August 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.